These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Novel phthalazinyl derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis isocitrate lyase enzyme.
    Author: Sriram D, Yogeeswari P, Senthilkumar P, Dewakar S, Rohit N, Debjani B, Bhat P, Veugopal B, Pavan VV, Thimmappa HM.
    Journal: Med Chem; 2009 Sep; 5(5):422-33. PubMed ID: 19534678.
    Abstract:
    Novel 2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydro-1-phthalazinyl]acetic acid hydrazones were synthesized from phthalic anhydride by a six step synthesis and evaluated for in vitro, in vivo activities against eight mycobacterial species and Mycobacterium tuberculosis (MTB) isocitrate lyase (ICL) enzyme inhibition studies. Among twenty six compounds N'1-[(4-nitrophenyl)methylene]-2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-1,2,3,4-tetrahydro-1-phthalazinyl]ethanohydrazide (7j) was found to be the most active compound in-vitro with MIC's of 0.18 and <0.09 microM against log-phase cultures of MTB and multi-drug resistant MTB respectively. Compound 7j inhibited all the eight mycobacterial species with MIC ranging from <0.09-12.25 microM and was not toxic to Vero cell lines till 122.5 microM. Seven compounds were tested against starved culture of MTB and they inhibited with MIC's ranging from 2.88-8.91 microM. Some compounds showed 45-61% inhibition against MTB ICL enzyme at 10 microM. In the in vivo animal model 7j decreased the bacterial load in lung and spleen tissues with 1.87 and 3.03-log10 protections respectively at 25 mg/kg body weight dose.
    [Abstract] [Full Text] [Related] [New Search]